IQVIA delivered an 8% year-over-year revenue increase in Q3, with results that outpaced Wall Street expectations and prompted a positive market reaction. Management attributed this performance to accelerated growth in both clinical and commercial segments, underscored by robust operational execution and higher win rates. CEO Ari Bousbib highlighted the company’s increased adoption of artificial intelligence (AI) solutions, which played a significant role in winning new business and improving productivity. Bousbib described clinical bookings as the strongest in four years, citing expanded use of AI-driven tools as a differentiator for clients seeking faster, more efficient studies.
Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).
IQVIA (IQV) Q3 2026 highlights:
- Revenue $4.43 billion vs S&P analysts’ estimates of $4.36 billion (8% year-on-year growth, 1.5% beat)
- Adjusted EPS $3.34 vs S&P analysts’ estimates of $3.28 (2% beat)
- Adjusted EBITDA $1.03 billion vs analyst estimates of $1.02 billion (23.3% margin, 1.6% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $17.43 billion at the midpoint from $17.38 billion
- Adjusted EPS guidance Management slightly raised its full-year adjusted EPS guidance to $12.95 at the midpoint
- EBITDA guidance $4.04 billion at the midpoint for the full year, in line with analyst expectations
- Operating margin 12.9%, in line with the same quarter last year
- Constant currency revenue rose 8.6% year on year (3.9% in the same quarter last year)
- Market capitalization $45.99 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from IQVIA’s Q3 earnings call
- Shlomo Rosenbaum (Stifel) asked about IQVIA’s unique ability to deploy data and technology in AI-driven workflows. CEO Ari Bousbib explained that proprietary data, deep life sciences expertise, and the ability to interpret and apply insights differentiate IQVIA from competitors.
- Elizabeth Anderson (Evercore ISI) inquired about the factors behind gross margin improvement despite a higher mix of pass-through revenues. CFO Michael J. Fedock detailed that operational improvements more than offset non-operational headwinds, highlighting an 80 basis point underlying margin gain.
- Jailendra Singh (Truist Securities) questioned the nature of strong Q3 clinical bookings and whether there were unusual factors or broad-based market strength. Bousbib confirmed broad-based growth, improved win rates, and strength in large pharma and EBP as key contributors.
- Eric Coldwell (Baird) sought clarification on below-the-line items, particularly interest expense and backlog adjustments. Fedock confirmed current interest expense as a reasonable baseline and described backlog adjustments as a clean-up of projects inactive for over 18 months.
- David Windley (Jefferies) asked about the recovery in R&D spending and the relative strength of biotech versus large pharma. Bousbib agreed biotech funding is leading the recovery, and that large pharma’s partnership renegotiations have left IQVIA better positioned for future growth.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will be watching (1) whether AI-enabled solutions continue to drive incremental clinical bookings and shorten project timelines, (2) sustained growth in commercial pipelines as new drug launches progress, and (3) the impact of further operational efficiency initiatives on EBITDA margin stability. Additionally, we will track any changes in biotech funding trends and the pace of backlog conversion as key indicators of underlying demand.
IQVIA currently trades at $272.50, in line with $273.49 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
